Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
Part of paid clinical trials in Duarte, California.
- Sponsor
- Bayer
- Study ID
- NCT04126733
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Regorafenib (Stivarga, BAY73-4506) — DRUGRegorafenib administered as oral tablets given every day for 3 weeks of each 28 days treatment cycle (i.e., 3 weeks on, 1 week off)
- Nivolumab (Opdivo) — BIOLOGICALAdministered on day 1 of every treatment cycle.
Study Details
The purpose of this study is to learn if combination of the two drugs regorafenib and nivolumab is an effective treatment for pMMR - MSS colorectal cancer, a special type of cancer of the colon or rectum (pMMR stands for proficient Mismatch Repair; MSS stands for Microsatellite Stable) and whether it is safe for patients. Regorafenib works by blocking several different proteins involved in tumor growth. Nivolumab is an immunotherapy drug encouraging the body's own immune system to attack cancer cells. Both drugs have been approved, but not for how they are being used as combination therapy in this study. Brand name of regorafenib is Stivarga; brand name of nivolumab is Opdivo.
Key Dates
- Start date
- Oct 14, 2019
- Status verified
- Jun 2023
- Primary completion
- Nov 11, 2020
- Completion
- Mar 28, 2022
Study Design
- Enrollment
- 70 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Regorafenib + Nivolumab
Primary Outcome Measure
Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator [ Time Frame: Through database cut-off date of 11-NOV-2020 (Primary Completion Date) (up to 13 months) ]
Locations (15)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | - |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | - |
| Miami Cancer Institute at Baptist Health South Florida | Miami | Florida | 33176 | - |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | - |
| Minnesota Oncology Hematology, PA | Minneapolis | Minnesota | 55404 | - |
| Nebraska Cancer Specialists | Papillion | Nebraska | 68046 | - |
| New York Oncology Hematology. P.C. | Albany | New York | 12206 | - |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | - |
| Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | - |
| Texas Oncology-Arlington North | Arlington | Texas | 76012 | - |
| Baylor Charles A. Sammons Cancer Center at Dallas | Dallas | Texas | 75246 | - |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | - |
| Texas Oncology-Sherman | Sherman | Texas | 75090 | - |
| Virginia Oncology Associates | Newport News | Virginia | 23606 | - |
| Northwest Cancer Specialists, PC | Vancouver | Washington | 98684 | - |
Find similar trials in Duarte, CA
Related Studies
- Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer PatientsRecruiting · Vanderbilt University Medical Center · Nashville, Tennessee
- ColoCare Study - Colorectal Cancer CohortRecruiting · University of Utah · Los Angeles, California
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas